CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conference:<\/p>\n
Chardan Virtual 4th Annual Genetic Medicines ConferenceFireside ChatDate: Monday, October 5, 2020Time: 10:30 a.m. ET<\/p>\n
The event will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available for approximately 30 days following the event.<\/p>\n
About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR\/Cas9 and CRISPR\/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit http:\/\/www.editasmedicine.com<\/a>.<\/p>\n Investor ContactMark Mullikin(617) 401-9083mark.mullikin@editasmed.com<\/a><\/p>\n Media ContactCristi Barnett(617) 401-0113cristi.barnett@editasmed.com<\/a><\/p>\n <\/p>\n Original post: <\/p>\n Editas Medicine to Participate in Upcoming Investor Conference - GlobeNewswire<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. Continue reading